Related Experiment Video
Updated: May 15, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
The risks and benefits of early immunosuppression and biological therapy
1The Dr. Henry D. Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY 10029, USA. bruce.sands @ mssm.edu
Abstract:
Crohn's disease and ulcerative colitis are heterogeneous conditions with highly variable courses of disease. Recent studies have focused on the time soon after diagnosis as a potential window of opportunity before which complicated disease behaviors have ensued and in which attaining adequate control of the inflammatory process might improve long-term outcomes. This review covers the use of immune suppression and biological therapy early in the course of inflammatory bowel disease. It includes the rationale for using these medications earlier, the features of early disease that may lead to improved outcomes with early intervention, the most optimal strategies for early treatment, the benefits of early intervention and the risks of this approach. In addition, we discuss the issue of which patients to choose for early intervention through risk stratification.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tumor Immunotherapy
Kidney Transplant I: Introduction
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

